{"id":"NCT01345240","sponsor":"GlaxoSmithKline","briefTitle":"Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)","officialTitle":"Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11-17","primaryCompletion":"2013-01-09","completion":"2017-02-09","firstPosted":"2011-05-02","resultsPosted":"2014-02-10","lastUpdate":"2019-07-18"},"enrollment":705,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Malaria","Malaria Vaccines"],"interventions":[{"type":"BIOLOGICAL","name":"GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049","otherNames":[]},{"type":"BIOLOGICAL","name":"Engerix-B™ vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix/Hib™ vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Polio Sabin™ vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Rotarix™ vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Synflorix™ vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Measles vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Yellow fever vaccine","otherNames":[]}],"arms":[{"label":"RTS,S Regimen A Lot 1 Group","type":"EXPERIMENTAL"},{"label":"RTS,S Regimen A Lot 2 Group","type":"EXPERIMENTAL"},{"label":"RTS,S Regimen A Lot 3 Group","type":"EXPERIMENTAL"},{"label":"RTS,S Regimen B Lot 1 Group","type":"EXPERIMENTAL"},{"label":"RTS,S Regimen B Lot 2 Group","type":"EXPERIMENTAL"},{"label":"RTS,S Regimen B Lot 3 Group","type":"EXPERIMENTAL"},{"label":"RTS,S Regimen C Lot 1 Group","type":"EXPERIMENTAL"},{"label":"RTS,S Regimen C Lot 2 Group","type":"EXPERIMENTAL"},{"label":"RTS,S Regimen C Lot 3 Group","type":"EXPERIMENTAL"},{"label":"Engerix B Regimen A Group","type":"ACTIVE_COMPARATOR"},{"label":"Engerix B Regimen B Group","type":"ACTIVE_COMPARATOR"}],"summary":"This study has been designed to support the indication of the candidate vaccine (also referred to as GSK 257049 or RTS,S in this record) against hepatitis B virus infection, when administered as a primary vaccination integrated into an Expanded Program on Immunization (EPI) regimen to infants living in sub-Saharan Africa.","primaryOutcome":{"measure":"Percentage of Seroprotected Subjects Against Anti-Hepatitis B (HBs) Antigen","timeFrame":"At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B","effectByArm":[{"arm":"RTS,S Group","deltaMin":100,"sd":null},{"arm":"Engerix B Group","deltaMin":96,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"8 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":17},"locations":{"siteCount":2,"countries":["Burkina Faso","Ghana"]},"refs":{"pmids":["29630438"],"seeAlso":["https://clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":142},"commonTop":["Pyrexia","Gastroenteritis","Malaria","Pain","Rhinitis"]}}